Canada - français - Health Canada

glaxosmithkline inc - urée; acétate d'hydrocortisone - crème - 10%; 1% - urée 10%; acétate d'hydrocortisone 1% - anti-inflammatory agents

Canada - français - Health Canada

glaxosmithkline inc - acétate d'hydrocortisone; urée - lotion - 1%; 10% - acétate d'hydrocortisone 1%; urée 10% - anti-inflammatory agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - betaxololum - augentropfensuspension - betaxololum 2.5 mg ut betaxololi hydrochloridum, natrii polystyrensulfonas, carbomerum 974p, mannitolum, acidum hydrochloridum aut natrii hydroxidum, aqua, ad suspensionem pro 1 ml. - le glaucome - synthetika

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

novartis pharma sa-nv - chlorhydrate de bétaxolol 2,8 mg/ml - eq. bétaxolol 2,5 mg/ml - collyre en suspension - 2,5 mg/ml - chlorhydrate de bétaxolol 2.8 mg/ml - betaxolol

Canada - français - Health Canada

baxter corporation - chlorhydrate de lidocaïne; chlorure de sodium - liquide - 1%; .9% - chlorhydrate de lidocaïne 1%; chlorure de sodium .9% - local anesthetics

Suisse - français - OFAG-BLW (Bundesamt für Landwirtschaft)

sintagro ag - méthylbutenol; (s)-cis-verbenol; ipsdiénol - vp produit diffuseur de vapeur - insecticide (phéromones)

Canada - français - Ecolab

ecolab deutschland gmbh -

Canada - français - Health Canada

fresenius kabi canada ltd - cisatracurium (bésilate de cisatracurium) - solution - 2mg - cisatracurium (bésilate de cisatracurium) 2mg - neuromuscular blocking agents

Union européenne - français - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.